6-9 September 2018 | Kaohsiung, Taiwan

20th Asia Pacific League of Associations for Rheumatology Congress

6-9 September 2018 | Kaohsiung, Taiwan

Beyond Gout: Hyperuricemia at cardio-renal perspective

An increasing body of evidence now suggests that hyperuricemia (i.e. elevated serum uric acid (sUA) levels) is an independent risk factor for several major chronic metabolic diseases including: hypertension, stroke, type 2 diabetes and chronic kidney diseases (CKD).
Elevated levels of sUA are an aetiological mechanism in development of gout and also significantly contribute to the increase in the relative risk of cardiovascular (CV) diseases, in addition to more consolidated CV risk factors. Compelling evidence from quasi-randomised studies suggests that treatment with urate-lowering therapies may be beneficial in reducing the risk of CV events. Moreover, recent randomised controlled trials have suggested a protective effect of urate-lowering therapy in preventing the progression of CKD.
This Astellas satellite symposium will explore the evidence base that suggests hyperuricemia should be a major target for intervention.
Chair
Prof Prof Wen-Chan Tsai, Kaohsiung Medical University Chung-Ho Memorial Hospital, APLAR 2018 Congress Chair
Speaker
Prof Claudio Borghi, University of Bologna
Dr. Titus Lau, National University Hospital-National University Health System
Agenda
1030 – Welcome and introduction – Chair
1035 – Management of Gout and hyperuricemia in Patients with Cardiovascular Diseases-Mutual Benefit or Unintended Consequences? – Prof. Claudio Borghi
1105 – Gout and chronic hyperuricemia at renal perspective – Prof. Titus Lau
1135 – Panel discussion and Q&A
1145 – Symposium close